Cytosorbents Corp 8K

CytoSorbents Corporation used an 8-K exhibit to present Q2 2026 results and strategic updates, highlighting improved margins, cost reductions, regulatory plans for DrugSorb-ATR and HemoDefend-BGA, and a goal of achieving operating cash flow breakeven in the second half of 2026.

CytoSorbents Corporation furnished an investor presentation for its August 6, 2026 Q2 2026 earnings conference call, outlining stable quarterly revenue of $9.6 million with improving gross margins to 73%, ongoing restructuring of its German direct sales force, progress toward operating cash flow breakeven in the second half of 2026, and the company’s four key value drivers: restoring growth in its CytoSorb business, obtaining U.S. FDA De Novo clearance for its investigational DrugSorb-ATR device (including plans for additional mechanistic and real-world evidence to support a resubmission and a potential parallel DOAC indication filing), and advancing its HemoDefend-BGA universal plasma filter through FDA clinical pathways and potential non-dilutive government funding. The presentation emphasizes non-GAAP metrics such as Adjusted EBITDA and Negative Free Cash Flow, describes the regulatory status of CytoSorb, DrugSorb-ATR, and HemoDefend-BGA, and discusses strategic and operational initiatives, including workforce and cost reductions, designed to optimize operations and achieve long‑term value creation.

Filing Facts

CIK

1175151

Ticker

-

Form

8K

Source Type

sec

Accession

0001104659-26-092691

Alert Tier

6